Erschienen in:
01.02.2011 | Letter
Mutation screening of RAD51C in male breast cancer patients
verfasst von:
Valentina Silvestri, Piera Rizzolo, Mario Falchetti, Ines Zanna, Giovanna Masala, Domenico Palli, Laura Ottini
Erschienen in:
Breast Cancer Research
|
Ausgabe 1/2011
Einloggen, um Zugang zu erhalten
Excerpt
We read with great interest the paper by Akbari and colleagues [
1] in a recent issue of
Breast Cancer Research. The authors reported on the absence of
RAD51C mutations in 454 patients with
BRCA1/2-negative familial breast cancer/ovarian cancer (BC/OC). In the initial report by Meindl and colleagues [
2],
RAD51C mutations were identified in 6 out of 480 patients with
BRCA1/2-negative familial BC/OC. Interestingly, on the basis of histopathologic features, including intermediate grade (G2), estrogen receptor-positive (ER
+), progesterone receptor-positive (PR
+), and HER2-negative (HER2
-) expression,
RAD51C-associated BCs were found to be similar to
BRCA2-associated BCs [
2].
BRCA2 is known to play a significant role in male BC (MBC); however, no occurrence of MBC was observed in the six
RAD51C families described [
2]. …